DYANAVEL XR, Quillivant XR, and QuilliChew ER are federally controlled substances (CII) because they can be abused or lead to dependence. Keep these medicines in a safe place to prevent misuse and abuse. Selling or giving away these medicines may harm others and is against the law. Tell your doctor if you, your child, or any family members have ever abused or been dependent on alcohol, prescription medicines, or street drugs.
QUILLIVANT XR® – SMOOTH RELEASE THROUGHOUT
Quillivant XR® (methylphenidate hydrochloride): After an initial rapid rise in blood levels, a gradual tapering off throughout the day with no additional peaks
Pharmacokinetics (PK) describes the way in which a person’s body absorbs, distributes, metabolizes, and excretes a medication. The PK properties of Quillivant XR were studied in healthy adults who were given 60 mg of Quillivant XR compared to an immediate-release (IR) liquid methylphenidate solution, in two equal doses of 30 mg each, 6 hours apart. Blood samples were collected before and then at several time points after taking the drug. The amount of methylphenidate in each sample was then measured in a laboratory.
As shown in the chart below, blood levels of methylphenidate increased rapidly after taking Quillivant XR, reaching a peak around 5 hours. Levels then gradually decreased from 5 hours through 24 hours.
Blood levels of methylphenidate in people who took the IR solution increased and decreased quickly. After a second dose of the IR solution, the blood levels again showed a quick rise and a quick drop off.
Unlike IR methylphenidate solutions, Quillivant XR provides steady levels throughout the day in a once-daily dose with no additional peaks.
Mean d-methylphenidate plasma concentration-time profiles
- The use of LiquiXR® technology gives Quillivant XR (methylphenidate HCl) approximately 20% immediate-release and 80% extended-release methylphenidate
LiquiXR® technology is an ion exchange polymer chemistry that enables continuous release of the medication throughout the day.